{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T22:24:53Z","timestamp":1778019893032,"version":"3.51.4"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Randomized clinical trials have demonstrated the safety and efficacy of ocriplasmin in patients with vitreomacular traction (VMT), including those with macular hole (MH). The INJECT study prospectively evaluated ocriplasmin in the setting of clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>INJECT was a Phase 4, multicenter, prospective observational study. Patients were followed up for 12 months. Assessments included nonsurgical VMT resolution, nonsurgical MH closure, best-corrected visual acuity, occurrence of vitrectomy, and adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The efficacy population (N = 395) received an ocriplasmin injection and had optical coherence tomography\u2013confirmed VMT at baseline. At Day 28, the rate of nonsurgical VMT resolution was 40.7% in the overall group, and the rate of nonsurgical MH closure was 36.0% in the VMT with MH group. At Month 12, the rate of \u22652-line best-corrected visual acuity gain (irrespective of vitrectomy) was 36.8% in the overall group and 59.6% in the VMT with MH group. The percentage of patients who underwent vitrectomy in the study eye was 29.1% in the overall group and 55.6% in the VMT with MH group. Photopsia (9.8%) and vitreous floaters (6.8%) were the most frequent adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The INJECT study showed that ocriplasmin is effective in a clinical setting in patients with VMT, with or without MH. No new safety signals were identified from this large and surgeon-selected patient group, although the significant limitations of the study design without an image reading center and scheduled study visit timings should be noted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000002862","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T03:08:18Z","timestamp":1591240098000},"page":"266-276","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE"],"prefix":"10.1097","volume":"41","author":[{"given":"David H. W.","family":"Steel","sequence":"first","affiliation":[{"name":"Sunderland Eye Infirmary, Sunderland, United Kingdom,; Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niall","family":"Patton","sequence":"additional","affiliation":[{"name":"Manchester Royal Eye Hospital, Manchester, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodor","family":"Stappler","sequence":"additional","affiliation":[{"name":"Fondation Asile des Aveugles, H\u00f4pital Ophtalmique Jules Gonin, Lausanne, Switzerland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niral","family":"Karia","sequence":"additional","affiliation":[{"name":"Southend University Hospital, Westcliff-on-Sea, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Hoerauf","sequence":"additional","affiliation":[{"name":"Augenklinik der Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishal","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kent and Canterbury Hospital, East Kent Hospitals University, Canterbury, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Wachtlin","sequence":"additional","affiliation":[{"name":"Augenheilkunde, Sankt Gertrauden-Krankenhaus GmbH, Berlin, Germany; Medizinische Hochschule Brandenburg Theodor Fontane, Neuruppin, Germany; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Raber","sequence":"additional","affiliation":[{"name":"Oxurion NV, Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Kozma-Wiebe","sequence":"additional","affiliation":[{"name":"Oxurion NV, Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the INJECT study investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"R1-20250609","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ajo.2009.11.022","article-title":"Posterior vitreous detachment: evolution and complications of its early stages","volume":"149","author":"Johnson","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R2-20250609","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/aos.13547","article-title":"Intravitreal gas for symptomatic vitreomacular adhesion: a synthesis of the literature","volume":"96","author":"Neffendorf","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"R3-20250609","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.ophtha.2016.06.043","article-title":"Results of the 2-year ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole (OASIS) randomized trial","volume":"123","author":"Dugel","year":"2016","journal-title":"Ophthalmology"},{"key":"R4-20250609","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1056\/NEJMoa1110823","article-title":"Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes","volume":"367","author":"Stalmans","year":"2012","journal-title":"N Engl J Med"},{"key":"R5-20250609","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ophtha.2014.07.045","article-title":"Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials","volume":"122","author":"Haller","year":"2015","journal-title":"Ophthalmology"},{"key":"R6-20250609","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3928\/23258160-20160808-04","article-title":"Baseline predictors of vitreomacular adhesion\/traction resolution following an intravitreal injection of ocriplasmin","volume":"47","author":"Jackson","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R7-20250609","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.oret.2018.07.011","article-title":"Ocriplasmin treatment leads to symptomatic vitreomacular adhesion\/vitreomacular traction resolution in the real-world setting: the phase IV ORBIT study","volume":"3","author":"Khanani","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"R8-20250609","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1097\/IAE.0000000000002332","article-title":"Assessment of anatomical and functional outcomes with ocriplasmin treatment in patients with vitreomacular traction with or without macular holes: results of OVIID-1 trial","volume":"39","author":"Tadayoni","year":"2019","journal-title":"Retina"},{"key":"R9-20250609","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3928\/23258160-20130715-05","article-title":"Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion","volume":"44","author":"Kim","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R10-20250609","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/bjophthalmol-2013-304219","article-title":"Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome","volume":"98","author":"Singh","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R11-20250609","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ajo.2015.01.034","article-title":"Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes","volume":"159","author":"Sharma","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R12-20250609","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000446842","article-title":"The Portuguese experience with ocriplasmin in clinical practice","volume":"56","author":"Figueira","year":"2016","journal-title":"Ophthalmic Res"},{"key":"R13-20250609","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s00417-017-3747-1","article-title":"Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice","volume":"255","author":"Schumann","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R14-20250609","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/IAE.0000000000001505","article-title":"Intravitreal ocriplasmin in clinical practice: predictors of success, visual outcomes, and complications","volume":"38","author":"Feng","year":"2018","journal-title":"Retina"},{"key":"R15-20250609","doi-asserted-by":"crossref","first-page":"e0197072","DOI":"10.1371\/journal.pone.0197072","article-title":"Intravitreal ocriplasmin for the treatment of vitreomacular traction and macular hole- A study of efficacy and safety based on NICE guidance","volume":"13","author":"Muqit","year":"2018","journal-title":"PLoS One"},{"key":"R16-20250609","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/bjophthalmol-2017-310874","article-title":"Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT study","volume":"102","author":"Paul","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R17-20250609","first-page":"403461","article-title":"Macular hole progression following ocriplasmin intravitreal injection","volume":"2014","author":"Casswell","year":"2014","journal-title":"Case Rep Ophthalmol Med"},{"key":"R18-20250609","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/jamaophthalmol.2013.8142","article-title":"Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection","volume":"132","author":"Fahim","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R19-20250609","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/eye.2016.195","article-title":"Real world outcomes of ocriplasmin use by members of the British and Eire Association of Vitreoretinal Surgeons","volume":"31","author":"Haynes","year":"2017","journal-title":"Eye (Lond)"},{"key":"R20-20250609","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/jamaophthalmol.2015.1680","article-title":"Zonular dehiscence at the time of combined vitrectomy and cataract surgery after intravitreal ocriplasmin injection","volume":"133","author":"Keller","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R21-20250609","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ajoc.2016.08.005","article-title":"Floaters and reduced contrast sensitivity after successful pharmacologic vitreolysis with ocriplasmin","volume":"4","author":"Khoshnevis","year":"2016","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R22-20250609","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1007\/s00417-016-3398-7","article-title":"Rhegmatogenous retinal detachment following intravitreal ocriplasmin","volume":"254","author":"Madi","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R23-20250609","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/ICB.0000000000000120","article-title":"Severe acute vision loss, dyschromatopsia, and changes in the ellipsoid zone on SD-OCT associated with intravitreal ocriplasmin injection","volume":"9","author":"Quezada Ruiz","year":"2015","journal-title":"Retin Cases Brief Rep"},{"key":"R24-20250609","first-page":"1591","article-title":"Retinal breaks due to intravitreal ocriplasmin","volume":"8","author":"Silva","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"R25-20250609","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/eye.2016.42","article-title":"Predicting macular hole closure with ocriplasmin based on spectral domain optical coherence tomography","volume":"30","author":"Steel","year":"2016","journal-title":"Eye (Lond)"},{"key":"R26-20250609","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00417-016-3404-0","article-title":"Ocriplasmin\u2014variable efficacy?","volume":"254","author":"Steel","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R27-20250609","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jamaophthalmol.2013.8258","article-title":"Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography","volume":"132","author":"Tibbetts","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R28-20250609","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.jcjo.2017.07.013","article-title":"Delayed transient corneal edema after intravitreal injection of ocriplasmin","volume":"53","author":"Zhang","year":"2018","journal-title":"Can J Ophthalmol"},{"key":"R29-20250609","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41433-019-0407-1","article-title":"Cochrane Corner: ocriplasmin\u2014why isn't it being used more?","volume":"33","author":"Grinton","year":"2019","journal-title":"Eye"},{"key":"R30-20250609","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/IAE.0000000000000448","article-title":"Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion\/traction","volume":"35","author":"Kaiser","year":"2015","journal-title":"Retina"},{"key":"R31-20250609","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/bjophthalmol-2014-305620","article-title":"Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?","volume":"99","author":"Hager","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R32-20250609","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/bjophthalmol-2019-314142","article-title":"Longitudinal ellipsoid zone and subretinal fluid mapping following ocriplasmin injection in the prospective observational ORBIT trial","volume":"104","author":"Lavine","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R33-20250609","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/IAE.0000000000000519","article-title":"Safety profile OF ocriplasmin for symptomatic vitreomacular adhesion: a comprehensive analysis of premarketing and postmarketing experiences","volume":"35","author":"Hahn","year":"2015","journal-title":"Retina"},{"key":"R34-20250609","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/IAE.0000000000001536","article-title":"Evaluation of full-field electroretinogram reductions after ocriplasmin treatment: results of the OASIS trial ERG substudy","volume":"38","author":"Birch","year":"2018","journal-title":"Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T16:01:29Z","timestamp":1749484889000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002862"}},"subtitle":["The INJECT Study"],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002862","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,2]]}}}